Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Azacitidine in Relapsed/Refractory T-Cell Large Granular Lymphocytic Leukemia
NCT05141682Phase 2Active, not recruiting
- Start
- Jun 2022
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CC-486 in T-cell large granular lymphocytic leukemia. Primary endpoints: Maximum Tolerated Dose and Overall Response Rate up to 3 years. Started Jun 2022; status: active, not recruiting.
02
Drugs
CC-486
03
Conditions
T-cell large granular lymphocytic leukemia
Beyond the preview
Go deeper on NCT05141682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05141682.